Raymond James analyst Timur Ivannikov downgraded AnaptysBio to Market Perform from Outperform without a price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANAB:
- AnaptysBio announces portfolio update, discloses $575M in cash to end 2022
- AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
- AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
- AnaptysBio, GSK announces Phase 3 RUBY trial results for JEMPERLI
- AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference